---
title: The Brits could have done better
description: UK-based pharmaphorum is covering the GLP-1 issue, but it played down our rather important point about the ease of compounding with the drugs.
---

[APC in the News ](https://a4pc.org/inthenews)

# [The Brits could have done better](https://a4pc.org/inthenews/2024-10/the-brits-could-have-done-better)

 Written by [Andrew](https://a4pc.org/inthenews/author/andrew) | Oct 23, 2024

UK-based pharmaphorum is covering the GLP-1 issue on this side of the pond — specifically Lilly’s and Novo’s rather silly contention that the injections are difficult to compound.

While [it quoted Scott](https://pharmaphorum.com/news/novo-joins-lilly-asking-fda-ban-glp-1-compounding) pointing out how Novo is deliberately conflating *creating* the semaglutide molecule with *compounding* with it, it used the weasel-word “claimed” rather than “said.” Still, we’ll take the international coverage.

[View full post](https://a4pc.org/inthenews/2024-10/the-brits-could-have-done-better)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Andrew"
  },
  "dateModified" : "2025-02-04T21:38:42.697Z",
  "datePublished" : "2024-10-23T10:45:24Z",
  "headline" : "The Brits could have done better",
  "image" : {
    "@type" : "ImageObject",
    "height" : 90,
    "url" : "https://join.a4pc.org/hubfs/pharmaphorum.png",
    "width" : 328
  },
  "mainEntityOfPage" : "https://a4pc.org/inthenews/2024-10/the-brits-could-have-done-better",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "APC in the News"
  }
}
```